BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.

Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz director, ...

Jefferies analyst Akash Tewari maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $150.00.

BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...

BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November ...

German biotech BioNTech saw its shares rise more than 3% to $114.98 pre-market today, as it reported financial results for the three months ended September 30, 2024, that beat expectations. Revenues ...

The week ahead holds earnings releases for many market-moving companies, including names such as Palantir and Super Micro ...

Mount Yale Investment Advisors LLC acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the third quarter, according to the company in its most recent 13F filing with the ...

Below is Validea's guru fundamental report for BIONTECH SE - ADR (BNTX). Of the 22 guru strategies we follow, BNTX rates highest using our Value Investor model based on the published strategy of ...

In the trading week from November 4th to 8th, experts opinion is between volatile to bearish in Dow Jones, S&P 500, and ...

BioNTech (BNTX) said on Monday that it expects full-year revenue at the low end of its guidance due in part to inventory write-downs, even as variant-adapted COVID-19 vaccines helped the German ...

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...